Alexandra L Jenkins1, Linda M Morgan2, Jacqueline Bishop2, Elena Jovanovski1,3, David J A Jenkins1,3,4,5, Vladimir Vuksan6,7,8,9. 1. Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. 2. Department of Nutritional Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, UK. 3. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 4. Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 5. Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada. 6. Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. v.vuksan@utoronto.ca. 7. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. v.vuksan@utoronto.ca. 8. Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. v.vuksan@utoronto.ca. 9. Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada. v.vuksan@utoronto.ca.
Abstract
PURPOSE: Use of polypharmacy in the treatment of diabetes is the norm; nonetheless, optimal control is often not achieved. Konjac-glucomannan-based fibre blend (KGB) and American ginseng (AG) have individually been shown to improve glycaemia and CVD risk factors in type 2 diabetes. The aim of this study was to determine whether co-administration of KGB and AG could improve diabetes control beyond conventional treatment. METHOD: Thirty-nine participants with type 2 diabetes (6.5 > A1c < 8.4%) were enrolled between January 2002 and May 2003 at the Risk Factor Modification Centre at St Michaels Hospital in a randomized, placebo-controlled, crossover trial with each intervention lasting 12-weeks. Medications, diet and lifestyle were kept constant. Interventions consisted of 6 g of fibre from KGB together with 3 g of AG (KGB and AG) or wheat bran-based, fibre-matched control. Primary endpoint was the difference in HbA1c levels at week 12. RESULTS:Thirty participants (18M:12F; age: 64 ± 7 years; BMI: 28 ± 5 kg/m2; HbA1c: 7.0 ± 1.0%) completed the study, and consumed 5.5 and 4.9 g/day of fibre from KGB and wheat bran control, respectively, and 2.7 g/day of AG. At week 12, HbA1c levels were 0.31% lower on the KGB and AG compared to control (p = 0.011). Mean (±SEM) plasma lipids decreased on the KGB and AG vs control by 8.3 ± 3.1% in LDL-C (p = 0.002), 7.5 ± 2.4% in non-HDL-C (p = 0.013), 5.7 ± 1.9% in total-C (p = 0.012), 4.1 ± 2.1% in total-C:HDL-C ratio (p = 0.042), 9.0 ± 2.3% in ApoB (p = 0.0005) and 14.6 ± 4.2% in ApoB:ApoA1 ratio (p = 0.049). CONCLUSIONS: Co-administration of KGB and AG increases the effectiveness of conventional therapy through a moderate but clinically meaningful reduction in HbA1c and lipid concentrations over 12 weeks in patients with type 2 diabetes. CLINICAL TRIALS REGISTRATION: NCT02806349 ( https://clinicaltrials.gov/ ).
RCT Entities:
PURPOSE: Use of polypharmacy in the treatment of diabetes is the norm; nonetheless, optimal control is often not achieved. Konjac-glucomannan-based fibre blend (KGB) and American ginseng (AG) have individually been shown to improve glycaemia and CVD risk factors in type 2 diabetes. The aim of this study was to determine whether co-administration of KGB and AG could improve diabetes control beyond conventional treatment. METHOD: Thirty-nine participants with type 2 diabetes (6.5 > A1c < 8.4%) were enrolled between January 2002 and May 2003 at the Risk Factor Modification Centre at St Michaels Hospital in a randomized, placebo-controlled, crossover trial with each intervention lasting 12-weeks. Medications, diet and lifestyle were kept constant. Interventions consisted of 6 g of fibre from KGB together with 3 g of AG (KGB and AG) or wheat bran-based, fibre-matched control. Primary endpoint was the difference in HbA1c levels at week 12. RESULTS: Thirty participants (18M:12F; age: 64 ± 7 years; BMI: 28 ± 5 kg/m2; HbA1c: 7.0 ± 1.0%) completed the study, and consumed 5.5 and 4.9 g/day of fibre from KGB and wheat bran control, respectively, and 2.7 g/day of AG. At week 12, HbA1c levels were 0.31% lower on the KGB and AG compared to control (p = 0.011). Mean (±SEM) plasma lipids decreased on the KGB and AG vs control by 8.3 ± 3.1% in LDL-C (p = 0.002), 7.5 ± 2.4% in non-HDL-C (p = 0.013), 5.7 ± 1.9% in total-C (p = 0.012), 4.1 ± 2.1% in total-C:HDL-C ratio (p = 0.042), 9.0 ± 2.3% in ApoB (p = 0.0005) and 14.6 ± 4.2% in ApoB:ApoA1 ratio (p = 0.049). CONCLUSIONS: Co-administration of KGB and AG increases the effectiveness of conventional therapy through a moderate but clinically meaningful reduction in HbA1c and lipid concentrations over 12 weeks in patients with type 2 diabetes. CLINICAL TRIALS REGISTRATION: NCT02806349 ( https://clinicaltrials.gov/ ).
Entities:
Keywords:
American ginseng; Dietary fibre; Glucomannan; Konjac mannan; Type 2 diabetes; Xanthan
Authors: Marion J Franz; John P Bantle; Christine A Beebe; John D Brunzell; Jean-Louis Chiasson; Abhimanyu Garg; Lea Ann Holzmeister; Byron Hoogwerf; Elizabeth Mayer-Davis; Arshag D Mooradian; Jonathan Q Purnell; Madelyn Wheeler Journal: Diabetes Care Date: 2002-01 Impact factor: 19.112
Authors: C Y Huang; M Y Zhang; S S Peng; J R Hong; X Wang; H J Jiang; F L Zhang; Y X Bai; J Z Liang; Y R Yu Journal: Biomed Environ Sci Date: 1990-06 Impact factor: 3.118
Authors: V Vuksan; J L Sievenpiper; R Owen; J A Swilley; P Spadafora; D J Jenkins; E Vidgen; F Brighenti; R G Josse; L A Leiter; Z Xu; R Novokmet Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: V Vuksan; D J Jenkins; P Spadafora; J L Sievenpiper; R Owen; E Vidgen; F Brighenti; R Josse; L A Leiter; C Bruce-Thompson Journal: Diabetes Care Date: 1999-06 Impact factor: 19.112
Authors: Andreea Zurbau; Lea Smircic Duvnjak; Sasa Magas; Elena Jovanovski; Jelena Miocic; Alexandra L Jenkins; David J A Jenkins; Robert G Josse; Lawrence A Leiter; John L Sievenpiper; Vladimir Vuksan Journal: Eur J Nutr Date: 2021-01-24 Impact factor: 5.614